ArticleMicroorganisms2023
Special Issue: Advances in SARS-CoV-2 Infection.
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Pooled it
- Article
- Integrating isothermal amplification with magnetic flocculation and DNA-guided PfAgo for SARS-CoV-2 detection.Frontiers in microbiology · 2026Article
- Proteomic Profiling of Human Peripheral Blood Cell Targets of IgG Induced by SARS-CoV-2: Insights into Vaccine Safety.Vaccines · 2025Article
- Serological surveillance for SARS-CoV-2 antibodies among students, faculty and staff within a large university system during the pandemic.World journal of virology · 2025Article
- Age-related immune response disparities between adults and children with severe COVID-19: a case-control study in China.Frontiers in microbiology · 2025Article
- Interactions of Probiotics with the Immune Cells of Patients with COVID-19 Pneumonia.Journal of innate immunity · 2025Article
- Severity-dependent IgG epitope profiling in COVID-19 reveals differential recognition of pathogen-derived antigens.Frontiers in immunology · 2025Article
- Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.Frontiers in pharmacology · 2024Article
- COVID-19 trends at the University of Tennessee: predictive insights from raw sewage SARS-CoV-2 detection and evaluation and PMMoV as an indicator for human waste.Frontiers in microbiology · 2024Article
- A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.Current topics in medicinal chemistry · 2024Review
- The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran.Frontiers in microbiology · 2024Article
- Current state-of-the-art and potential future therapeutic drugs against COVID-19.Frontiers in cell and developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus Disease 2019 (COVID-19) is a life-threatening disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus which was first reported in late 2019 in China, from where it then spread worldwide [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.